ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
In hematology, this year’s highlights encompassed several cutting-edge research directions—from unraveling the mechanisms of CAR-T resistance and exploring dual-target immunotherapies that may enhance precision and efficacy, to studies on treatment-free remission in multiple myeloma, and the creation of single-cell immune atlases offering novel insights into hematologic disease mechanisms. These achievements collectively reflect the continued progress and innovation in biomedical science and bring new hope for patients with hematologic malignancies.









